Calcitonin measurement and immunoassay interference: a case report and literature review

Abstract Calcitonin (CT) is currently the most sensitive serological marker of C-cell disease [medullary thyroid carcinoma (MTC) and C-cell hyperplasia]. Starting with a report on a case that occurred at our institution, this review focuses on trying to explain the reasons behind the poor specificity and sensitivity of the various CT immunoassays. A 15-year-old patient was referred to our institution in May 2014 for moderately elevated CT levels. Thyroid ultrasonography (US) documented a colloidal goiter. Secondary causes of the hypercalcitoninemia (hyperCT) were ruled out. The mismatch between the clinical picture and the laboratory results prompted us to search for other reasons for the patient’s high CT levels, so we applied the heterophilic blocking tube (HBT) procedure to the patient’s sera before the CT assay. Using this pretreatment step, his serum CT concentration dropped to <1 ng/L, as measured at the same laboratory. Measuring plasma CT has an important role in screening for C-cell disease, but moderately elevated serum CT levels need to be placed in their clinical context, bearing in mind all the secondary causes of C-cell hyperplasia and the possibility of laboratory interference, before exposing patients to the risks and costs of further tests.

[1]  J. Vieira,et al.  Macrocalcitonin Is a Novel Pitfall in the Routine of Serum Calcitonin Immunoassay. , 2016, The Journal of clinical endocrinology and metabolism.

[2]  P. Trimboli,et al.  Use of fine‐needle aspirate calcitonin to detect medullary thyroid carcinoma: A systematic review , 2016, Diagnostic cytopathology.

[3]  Douglas B. Evans,et al.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. , 2015, Thyroid : official journal of the American Thyroid Association.

[4]  P. Trimboli,et al.  Procalcitonin for detecting medullary thyroid carcinoma: a systematic review. , 2015, Endocrine-related cancer.

[5]  G. Cevenini,et al.  Reference range of serum calcitonin in pediatric population. , 2015, The Journal of clinical endocrinology and metabolism.

[6]  P. Trimboli,et al.  Detection rate of FNA cytology in medullary thyroid carcinoma: a meta‐analysis , 2015, Clinical endocrinology.

[7]  R. Vigneri,et al.  Cardiac arrest after intravenous calcium administration for calcitonin stimulation test. , 2014, Thyroid : official journal of the American Thyroid Association.

[8]  M. Pelizzo,et al.  Refining calcium test for the diagnosis of medullary thyroid cancer: cutoffs, procedures, and safety. , 2014, The Journal of clinical endocrinology and metabolism.

[9]  P. Trimboli,et al.  Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: a retrospective multicentre study , 2014, Clinical endocrinology.

[10]  P. Trimboli,et al.  Comparison of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among patients with thyroid nodules , 2013, Clinical chemistry and laboratory medicine.

[11]  R. Castello,et al.  Thyroid volume influences serum calcitonin levels in a thyroid-healthy population: results of a 3-assay, 519 subjects study , 2012, Clinical chemistry and laboratory medicine.

[12]  M. Pelizzo,et al.  Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. , 2012, The Journal of clinical endocrinology and metabolism.

[13]  C. Sturgeon,et al.  Analytical error and interference in immunoassay: minimizing risk , 2011, Annals of clinical biochemistry.

[14]  M. Rugge,et al.  Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. , 2011, European journal of endocrinology.

[15]  L. Giovanella,et al.  Spurious hypercalcitoninemia and heterophilic antibodies in patients with thyroid nodules , 2011, Head & neck.

[16]  P. Perros,et al.  2009 American Thyroid Association guidelines on thyroid nodules. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

[17]  S. Kim,et al.  Spurious hypercalcitoninemia in patients with nodular thyroid disease induced by heterophilic antibodies , 2009, Head & neck.

[18]  M. Luster,et al.  Potency and tolerance of calcitonin stimulation with high-dose calcium versus pentagastrin in normal adults. , 2009, The Journal of clinical endocrinology and metabolism.

[19]  H. Gharib,et al.  Medullary thyroid cancer: management guidelines of the American Thyroid Association. , 2009, Thyroid : official journal of the American Thyroid Association.

[20]  P. Caron,et al.  Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking. , 2007, European journal of endocrinology.

[21]  J. Lee,et al.  Diffuse sclerosing variant of papillary carcinoma of the thyroid: imaging and cytologic findings. , 2007, Thyroid : official journal of the American Thyroid Association.

[22]  M. Tommasi,et al.  Comparison of calcitonin determinations by polyclonal and monoclonal IRMAs. , 2007, Clinical chemistry.

[23]  R. Sherwood,et al.  Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial , 1992, Cell Biophysics.

[24]  H. Karga,et al.  Heterophilic antibodies causing falsely high serum calcitonin values , 2006, Journal of endocrinological investigation.

[25]  S. Berson,et al.  General principles of radioimmunoassay. 1968. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[26]  M. Langlois,et al.  "Hook effect" in calcitonin immunoradiometric assay in patients with metastatic medullary thyroid carcinoma: case report and review of the literature. , 2006, The Journal of clinical endocrinology and metabolism.

[27]  A. Ismail A radical approach is needed to eliminate interference from endogenous antibodies in immunoassays. , 2005, Clinical chemistry.

[28]  D. O'Kane,et al.  Prevalence of heterophilic antibody interference in eight automated tumor marker immunoassays. , 2005, Clinical chemistry.

[29]  E. Mallet,et al.  Reference intervals for serum calcitonin in men, women, and children. , 2004, Clinical chemistry.

[30]  J. White,et al.  Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. , 2004, The Journal of clinical endocrinology and metabolism.

[31]  E. Seregni,et al.  Evaluation of Circulating Calcitonin: Analytical Aspects , 2003, Tumori.

[32]  S. S. Levinson,et al.  Towards a better understanding of heterophile (and the like) antibody interference with modern immunoassays. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[33]  V. Marks,et al.  False-positive immunoassay results: a multicenter survey of erroneous immunoassay results from assays of 74 analytes in 10 donors from 66 laboratories in seven countries. , 2002, Clinical chemistry.

[34]  J. Barth,et al.  Interference in immunoassay is an underestimated problem , 2002, Annals of clinical biochemistry.

[35]  M. Mannelli,et al.  False serum calcitonin high levels using a non-competitive two-site IRMA , 2001, Journal of endocrinological investigation.

[36]  A. Remaley,et al.  A case of spurious hypercalcitoninemia: A cautionary tale on the use of plasma calcitonin assays in the screening of patients with thyroid nodules for neoplasia , 2001, Journal of endocrinological investigation.

[37]  A. Bockisch,et al.  Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. , 2000, The Journal of clinical endocrinology and metabolism.

[38]  L. Cole,et al.  False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrations , 2000, The Lancet.

[39]  L J Kricka,et al.  Human anti-animal antibody interferences in immunological assays. , 1999, Clinical chemistry.

[40]  I. Kaplan,et al.  When is a heterophile antibody not a heterophile antibody? When it is an antibody against a specific immunogen. , 1999, Clinical chemistry.

[41]  D. Chappard,et al.  Sex-related C cell hyperplasia in the normal human thyroid: a quantitative autopsy study. , 1997, The Journal of clinical endocrinology and metabolism.

[42]  G. Hör,et al.  Activating anti‐idiotypic human anti‐mouse antibodies for immunotherapy of ovarian carcinoma , 1994, Cancer.

[43]  L. Boscato,et al.  Heterophilic antibodies: a problem for all immunoassays. , 1988, Clinical chemistry.

[44]  P. J. Howanitz,et al.  Incidence and mechanism of spurious increase in serum thyrotropin. , 1982, Clinical chemistry.

[45]  P. Thomopoulos,et al.  False hyperthyrotropinemia induced by heterophilic antibodies against rabbit serum. , 1981, The Journal of clinical endocrinology and metabolism.

[46]  R. Dawkins,et al.  Population Study of Heterophile Antibodies , 1980, Vox sanguinis.

[47]  S. Berson,et al.  General principles of radioimmunoassay. , 1968, Clinica chimica acta; international journal of clinical chemistry.

[48]  C. Hales,et al.  Labelled Antibodies and Immunological Assay Systems , 1968, Nature.

[49]  A. Cameron,et al.  Delay in seeking treatment for mammary tumors , 1968, Cancer.